Role of bevacizumab in colorectal cancer growth and its adverse effects: A review

World Journal of Gastroenterology

Volumn 19, Issue 31, 2013, Pages 5051-5060

  Pavlidis, Efstathios T ^a   Pavlidis, Theodoros E ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Anti angiogenic agents; Avastin; Bevacizumab; Cancer targeted therapy; Colorectal cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTERIAL THROMBOEMBOLISM; BLEEDING; BREAST CANCER; BREAST METASTASIS; BRONCHOSPASM; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; COLITIS; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; FLUSHING; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INTESTINE PERFORATION; LEUKOENCEPHALOPATHY; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RIGOR; SEPSIS; SIDE EFFECT; STOMACH PERFORATION; SWEAT; SYSTEMATIC REVIEW (TOPIC); THORAX PAIN; THROMBOSIS; WOUND DEHISCENCE; WOUND HEALING; WOUND HEALING IMPAIRMENT; WOUND INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84882253119     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i31.5051     Document Type: Review

References (105)

1. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol 2011; 62: 444-455. [PMID: 22069106]
2. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B. Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology. Endokrynol Pol 2011; 62: 456-464. [PMID: 22069107]
3. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 2011; 34: 1785-1788. [PMID: 22130231 DOI: 10.1248/bpb.34.1785]
4. Ichihara E, Kiura K, Tanimoto M. Targeting angiogenesis in cancer therapy. Acta Med Okayama 2011; 65: 353-362. [PMID: 22189475]
5. Bruce D, Tan PH. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Cell Commun Adhes 2011; 18: 85-103. [PMID: 22017472]
6. Linkous AG, Yazlovitskaya EM. Novel therapeutic approaches for targeting tumor angiogenesis. Anticancer Res 2012; 32: 1-12. [PMID: 22213282]
7. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011; 81 Suppl 1: 24-29. [PMID: 22212932 DOI: 10.1159/000333256]
8. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg 2006; 93: 1456-1463. [PMID: 17115389 DOI: 10.1002/bjs.5624]
9. Konno H, Tanaka T, Baba M, Kanai T, Matsumoto K, Kamiya K, Nakamura S, Baba S. Quantitative analysis of vascular endothelial growth factor in colon cancer. Clinical and experimental. Eur Surg Res 1998; 30: 273-278. [PMID: 9704754 DOI: 10.1159/000008587]
10. Doger FK, Meteoglu I, Tuncyurek P, Okyay P, Cevikel H. Does the EGFR and VEGF expression predict the prognosis in colon cancer? Eur Surg Res 2006; 38: 540-544. [PMID: 17085940 DOI: 10.1159/000096774]
11. Konno H, Baba M, Tanaka T, Kamiya K, Ota M, Oba K, Shoji A, Kaneko T, Nakamura S. Overexpression of vascular endothelial growth factor is responsible for the hematogenous recurrence of early-stage gastric carcinoma. Eur Surg Res 2000; 32: 177-181. [PMID: 10878459 DOI: 10.1159/000008760]
12. Ciprandi G, Murdaca G, Colombo BM, De Amici M, Marseglia GL. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 2008; 69: 510-512. [PMID: 18577409 DOI: 10.1016/ j.humimm.2008.05.010]
13. Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008; 63: 945-946. [PMID: 18588566 DOI: 10.1111/j.1398-9995.2008.01727.x]
14. Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013; 5: 113-115. [PMID: 23413901 DOI: 10.2217/ imt.12.151]
15. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009; 66: 999-1013. [PMID: 19451611 DOI: 10.2146/ajhp080455]
16. Krämer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32: 1-14. [PMID: 17286784 DOI: 10.1111/j.1365-2710.2007.00800.x]
17. McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005; 48: 1632-1650. [PMID: 15906130 DOI: 10.1007/s10350-005-0026-8]
18. McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs 2008; 68: 487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009]
19. Kocáková I, Kocák I, Svoboda M, Nemecek R, Rehák Z, Standara M. Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer. Klin Onkol 2009; 22: 73-76. [PMID: 19522377]
20. Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010; 102: 495-499. [PMID: 20051952 DOI: 10.1038/sj.bjc.6605514]
21. Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol 2009; 27: 5499-5505. [PMID: 19858399 DOI: 10.1200/JCO.2008.21.5384]
22. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259]
23. Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol 2010; 27: 585-591. [PMID: 19526201 DOI: 10.1007/s12032-009-9253-5]
24. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
25. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65. [PMID: 12506171 DOI: 10.1200/JCO.2003.10.066]
26. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc MP, Watier H. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64: 210-225. [PMID: 17624800 DOI: 10.1016/j.critrevonc.2007. 04.011]
27. Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 2007; 13: 276-281. [PMID: 17921724 DOI: 10.1097/ PPO.0b013e3181570062]
28. Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15: 449-456. [PMID: 19152449 DOI: 10.3748/wjg.15.449]
29. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91: 173-180. [PMID: 16118771]
30. Bège T, Lelong B, Viret F, Turrini O, Guiramand J, Topart D, Moureau-Zabotto L, Giovannini M, Gonçalves A, Delpero JR. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients. Ann Surg Oncol 2009; 16: 856-860. [PMID: 19156464 DOI: 10.1245/ s10434-008-0279-2]
31. Li J, Saif MW. Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics 2009; 3: 429-441. [PMID: 19774210]
32. Welch S, Spithoff K, Rumble RB, Maroun J. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010; 21: 1152-1162. [PMID: 19942597 DOI: 10.1093/annonc/mdp533]
33. Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 2010; 21: 297-304. [PMID: 19940012 DOI: 10.1093/annonc/mdp489]
34. Koukourakis MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, Sivridis E, Harris AL. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res 2009; 15: 7069-7076. [PMID: 19887481 DOI: 10.1158/1078-0432. CCR-09-0688]
35. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198. [PMID: 20516443 DOI: 10.1200/ JCO.2009.27.7723]
36. Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P, Sperduti I, Giannarelli D, Cognetti F. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res 2010; 29: 58. [PMID: 20504361 DOI: 10.1186/1756-9966-29-58]
37. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as secondline treatment of colorectal cancer. Oncologist 2007; 12: 356-361. [PMID: 17405901 DOI: 10.1634/theoncologist.12-6-713]
38. García Alfonso P, Muñoz Martin A, Alvarez Suarez S, Blanco Codeidido M, Mondejar Solis R, Tapia Rico G, López Martín P, Martin M. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. Onkologie 2013; 36: 363-367. [PMID: 23774151 DOI: 10.1159/000351240]
39. Lv C, Wu S, Zheng D, Wu Y, Yao D, Yu X. The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials. Cancer Biother Radiopharm 2013; 28: 501-509. [PMID: 23768086 DOI: 10.1089/ cbr.2012.1458]
40. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16. [PMID: 20940184 DOI: 10.1200/ JCO.2010.30.0855]
41. Dewdney A, Cunningham D, Barbachano Y, Chau I. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer 2012; 106: 1718-1721. [PMID: 22531628 DOI: 10.1038/bjc.2012.152]
42. Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 2010; 15: 845-851. [PMID: 20667969 DOI: 10.1634/theoncologist.2010-0030]
43. Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, Sikov W, McNulty B, Shipley J, Anderson E, Khurshid H, Oconnor B, Oldenburg NB, Radie-Keane K, Husain S, Safran H. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82: 124-129. [PMID: 20947267 DOI: 10.1016/j.ijrobp.2010.08.005]
44. Zafar SY, Malin JL, Grambow SC, Abbott DH, Schrag D, Kolimaga JT, Zullig LL, Weeks JC, Fouad MN, Ayanian JZ, Wallace R, Kahn KL, Ganz PA, Catalano P, West DW, Provenzale D. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. BMC Cancer 2011; 11: 354. [PMID: 21846341 DOI: 10.1186/1471-24 07-11-354]
45. Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF, Zhao L, Nicol SJ. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs 2012; 30: 772-778. [PMID: 21120580 DOI: 10.1007/s10637-010-9598-9]
46. Dacosta Byfield S, Yu E, Morlock R, Evans D, Teitelbaum A. Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents. J Med Econ 2013; 16: 1071-1081. [PMID: 23777222]
47. Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 2009; 6: 375-383. [PMID: 19528960 DOI: 10.1038/nrurol.2009.102]
48. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714. [PMID: 18669456]
49. Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F. Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 2009; 16: 675-702. [PMID: 19525314 DOI: 10.1677/ ERC-08-0208]
50. Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R. Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. Oncologist 2012; 17: e13-e17. [PMID: 22744818 DOI: 10.1634/theoncologist. 2012-0115]
51. Tanne JH. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ 2011; 343: d7684. [PMID: 22121166 DOI: 10.1136/bmj.d7684]
52. Rose S. FDA pulls approval for avastin in breast cancer. Cancer Discov 2011; 1: OF1-OF2. [PMID: 22586694 DOI: 10.1158/2159-8290.CD-ND112311OL-08]
53. Dawood S, Shaikh AJ, Buchholz TA, Cortes J, Cristofanilli M, Gupta S, Gonzalez-Angulo AM. The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer 2012; 118: 2780-2786. [PMID: 22614656 DOI: 10.1002/cncr.26579]
54. Shamloo BK, Chhabra P, Freedman AN, Potosky A, Malin J, Weiss Smith S. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf 2012; 35: 507-518. [PMID: 22612854 DOI: 10.2165/11597600-000000000-00000]
55. Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs 2013; 18: 137-153. [PMID: 23668489 DOI: 10.1517/1472 8214.2013.794784]
56. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729. [PMID: 17947719 DOI: 10.1200/JCO.2007.12.2440]
57. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745. [PMID: 19114704 DOI: 10.1200/JCO.2008.16.3055]
58. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740. [PMID: 19720927 DOI: 10.1200/JCO.2008.19.8721]
59. Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011; 28: 334-340. [PMID: 21432029 DOI: 10.1007/ s12325-011-0007-3]
60. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Antiangiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 2009; 114: 431-436. [PMID: 19524286 DOI: 10.1016/j.ygyno.2009.04.021]
61. Rossi A, Maione P, Colantuoni G, Ferrara C, Rossi E, Guerriero C, Nicolella D, Falanga M, Palazzolo G, Gridelli C. Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol 2009; 6: 91-102. [PMID: 19519336 DOI: 10.2174/157016309788488339]
62. Samaranayake H, Määttä AM, Pikkarainen J, Ylä-Herttuala S. Future prospects and challenges of antiangiogenic cancer gene therapy. Hum Gene Ther 2010; 21: 381-396. [PMID: 20163246 DOI: 10.1089/hum.2010.017]
63. Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14: 7781-7789. [PMID: 19047105 DOI: 10.1158/1078-0432.CCR-08-0243]
64. Delli Carpini J, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010; 13: 43-58. [PMID: 20229258 DOI: 10.1007/ s10456-010-9163-3]
65. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs 2012; 30: 1597-1606. [PMID: 21629990 DOI: 10.1007/ s10637-011-9691-8]
66. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009; 27: 4096-4102. [PMID: 19636002 DOI: 10.1200/JCO.2009.21.8529]
67. Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, Simons R, Atabek U. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009; 62: 707-709. [PMID: 19461291 DOI: 10.1097/ SAP.0b013e3181828141]
68. Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal? Eur J Cancer 2009; 45: 2452-2461. [PMID: 19643598 DOI: 10.1016/ j.ejca.2009.06.028]
69. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239. [PMID: 17686822 DOI: 10.1093/jnci/djm086]
70. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27: 4865-4873. [PMID: 19704059 DOI: 10.1200/JCO.2009.22.3875]
71. Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K, Kuboki Y, Ichimura T, Ozaka M, Ogura M, Fujiwara Y, Matsueda K, Konishi F, Hatake K. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol 2010; 27: 807-814. [PMID: 19697164 DOI: 10.1007/s12032-009-9289-6]
72. Lemmens L, Claes V, Uzzell M. Managing patients with metastatic colorectal cancer on bevacizumab. Br J Nurs 2008; 17: 944-949. [PMID: 18983014]
73. Smith MS, Browne JD. The effect of endothelial cell growth factor on peripheral nerve regeneration. Otolaryngol Head Neck Surg 1998; 118: 178-182. [PMID: 9482548 DOI: 10.1016/ S1470-2045(09)70112-3]
74. Collins D, Ridgway PF, Winter DC, Fennelly D, Evoy D. Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy. Eur J Surg Oncol 2009; 35: 444-446. [PMID: 18417314 DOI: 10.1016/j.ejso.2008.02.013]
75. August DA, Serrano D, Poplin E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 2008; 97: 180-185. [PMID: 18095268 DOI: 10.1002/jso.20938]
76. Akkouche A, Sidéris L, Leblanc G, Leclerc YE, Vafiadis P, Dubé P. Complications after colorectal anastomosis in a patient with metastatic rectal cancer treated with systemic chemotherapy and bevacizumab. Can J Surg 2008; 51: E52-E53. [PMID: 18682755]
77. Abbrederis K, Kremer M, Schuhmacher C. Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery. Chirurg 2008; 79: 351-355. [PMID: 17453167 DOI: 10.1007/s00104-007-1339-z]
78. Lazzati V, Zygoń J, Lohsiriwat V, Veronesi P, Petit JY. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab. Aesthetic Plast Surg 2010; 34: 796-797. [PMID: 20567970 DOI: 10.1007/ s00266-010-9535-5]
79. Gamboa EO, Rehmus EH, Haller N. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. Clin Colorectal Cancer 2010; 9: 55-58. [PMID: 20100690 DOI: 10.3816/CCC.2010.n.008]
80. Grenader T, Goldberg A, Verstandig A, Shavit L. Indwelling central venous access port insertion during bevacizumab- based therapy. Anticancer Drugs 2010; 21: 704-707. [PMID: 20517148]
81. Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D. Antiangiogenic agents and late anastomotic complications. J Surg Oncol 2010; 101: 180-183. [PMID: 19953576]
82. Mariani P. The safety of perioperative bevacizumab use. J Chir (Paris) 2010; 147 Suppl 1: S12-S17. [PMID: 20172200 DOI: 10.1016/S0021-7697(10)70003-X]
83. Pavlidis ET, Ballas KD, Symeonidis NG, Psarras K, Koliakos G, Kouzi-Koliakos K, Topouridou K, Rafailidis SF, Pavlidis TE, Marakis GN, Sakantamis AK. The effect of bevacizumab on colon anastomotic healing in rats. Int J Colorectal Dis 2010; 25: 1465-1473. [PMID: 20689957 DOI: 10.1007/s00384- 010-1039-x]
84. Pavlidis ET, Ballas KD, Psarras K, Symeonidis NG, Koliakos G, Kouzi-Koliakos K, Rafailidis SF, Pavlidis TE, Marakis GN, Sakantamis AK. Intraperitoneal administration of bevacizumab intraoperatively does not affect abdominal wound healing in rats. Eur Surg Res 2011; 47: 45-51. [PMID: 21606651 DOI: 10.1159/000327970]
85. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010; 15: 1179-1191. [PMID: 21045188 DOI: 10.1634/ theoncologist.2009-0155]
86. Mizobe T, Ogata Y, Murakami H, Akagi Y, Ishibashi N, Mori S, Sasatomi T, Shirouzu K. Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep 2008; 20: 517-523. [PMID: 18695900]
87. Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem 2010; 53: 452-459. [PMID: 19928864 DOI: 10.1021/jm901427g]
88. Bäuerle T, Hilbig H, Bartling S, Kiessling F, Kersten A, Schmitt-Gräff A, Kauczor HU, Delorme S, Berger MR. Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia 2008; 10: 511-520. [PMID: 18472968]
89. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, Wendland MF, McDonald DM, Brasch RC. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008; 247: 391-399. [PMID: 18372448 DOI: 10.1148/radiol.2472070363]
90. Raatschen HJ, Fu Y, Rogut V, Simon GH, Sennino B, Wolf KJ, Brasch RC. Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors. Rofo 2010; 182: 133-139. [PMID: 19862658 DOI: 10.1055/s-0028-1109753]
91. Woodrum C, Nobil A, Dabora SL. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis re- lated tumors. J Transl Med 2010; 8: 14. [PMID: 20146790 DOI: 10.1186/1479-5876-8-14]
92. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010; 12: 233-242. [PMID: 20167811 DOI: 10.1093/neuonc/nop027]
93. Salaun PY, Bodet-Milin C, Frampas E, Oudoux A, Saï-Maurel C, Faivre-Chauvet A, Barbet J, Paris F, Kraeber-Bodéré F. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer 2010; 116: 1053-1058. [PMID: 20127950 DOI: 10.1002/cncr.24792]
94. Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Kinuya S, Yashiro M, Hirakawa K, Ohta T. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol 2010; 66: 745-753. [PMID: 20033809 DOI: 10.1007/s00280-009-1219-y]
95. Ninomiya S, Inomata M, Tajima M, Ali AT, Ueda Y, Shiraishi N, Kitano S. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res 2009; 154: 196-202. [PMID: 19329124 DOI: 10.1016/j.jss.2008.08.017]
96. Imaizumi T, Aoyagi K, Miyagi M, Shirouzu K. Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today 2010; 40: 851-857. [PMID: 20740349 DOI: 10.1007/s00595-009- 4154-y]
97. Okada Y, Akisue T, Hara H, Kishimoto K, Kawamoto T, Imabori M, Kishimoto S, Fukase N, Onishi Y, Kurosaka M. The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model. Anticancer Res 2010; 30: 3391-3395. [PMID: 20944113]
98. Shah DK, Veith J, Bernacki RJ, Balthasar JP. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol 2011; 68: 951-958. [PMID: 21305289 DOI: 10.1007/s00280-011-1566-3]
99. Davies S, Dai D, Pickett G, Thiel KW, Korovkina VP, Leslie KK. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. Oncol Rep 2011; 25: 855-862. [PMID: 21240464]
100. Kenmotsu H, Yasunaga M, Goto K, Nagano T, Kuroda J, Koga Y, Takahashi A, Nishiwaki Y, Matsumura Y. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 2010; 116: 4597-4604. [PMID: 20572031 DOI: 10.1002/cncr.25233]
101. Zhang J, Silva T, Yarovinsky T, Manes TD, Tavakoli S, Nie L, Tellides G, Pober JS, Bender JR, Sadeghi MM. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 2010; 107: 408-417. [PMID: 20538685 DOI: 10.1161/CIRCRESAHA. 109.210963]
102. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab. Int J Cancer 2011; 128: 920-926. [PMID: 20473899 DOI: 10.1002/ ijc.25409]
103. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, Mc- Clatchey AI, Plotkin SR, Jain RK, di Tomaso E. Antivascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 2010; 70: 3483-3493. [PMID: 20406973 DOI: 10.1158/0008-5472.CAN-09-3107]
104. Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 2009; 29: 284-290. [PMID: 18482274 DOI: 10.1111/j.1478-3231.2008.01762.x]
105. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011; 102: 117-121. [PMID: 21070475 DOI: 10.1111/ j.1349-7006.2010.01763.x]